Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study
Background: Guideline-directed medical therapy in patients with systolic heart failure (HF) has demonstrated improvement in morbidity and mortality rates. The FDA approved sacubitril/valsartan in 2015 to reduce the risk of cardiovascular death and hospitalization for HF. Objective: The purpose of...
Saved in:
Main Authors: | Roda Plakogiannis, Abraham Stefanidis, Nubriel Hernandez, Etty Vider |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2025-02-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/6428 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
by: Simone Mazzetti, et al.
Published: (2020-06-01) -
Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01) -
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
by: Rolf Wachter, et al.
Published: (2020-06-01) -
Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01) -
ELDERLY PATIENT WITH CHRONIC HEART FAILURE IN THE GENERAL PRACTICE
by: V.V. Zhdan, et al.
Published: (2017-03-01)